Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

450
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
450
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

464
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
464
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

520
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
520
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

727
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
727
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

777
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
777

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Analysis of Gut Microbiome Composition and Blood Lipid Profiles in Intensively Reared Broiler Chickens and Ducks.

Animals : an open access journal from MDPI·2026
Same author

Alleviation of heat stress-induced microbial dysbiosis in pigs through dietary supplementation with vitamins and trace elements.

Animal microbiome·2026
Same author

Analytical validation of a highly accurate and reliable next-generation sequencing-based urine assay.

Microbiology spectrum·2026
Same author

Protocol for the assessment of the impact of mycotoxins and glyphosate residues on the gut microbiome and resistome of European fallow deer.

STAR protocols·2026
Same author

Correction: Analytical validation of a metagenomic next-generation diagnostic platform for urinary tract infection in a Thai tertiary hospital setting: a BI-Biotia UTI cohort study.

Frontiers in cellular and infection microbiology·2026
Same author

Longitudinal source-sink dynamics of fecal litter and farm indoor environmental resistomes in broiler chicken and Cherry Valley ducks.

Animal microbiome·2026

Related Experiment Video

Updated: Dec 18, 2025

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.4K

Allithiamine Alleviates Hyperglycaemia-Induced Endothelial Dysfunction.

Attila Biró1, Arnold Markovics1, Mónika Éva Fazekas1

  • 1Institute of Food Technology, Faculty of Agricultural and Food Sciences and Environmental Management, University of Debrecen, H-4032 Debrecen, Hungary.

Nutrients
|June 11, 2020
PubMed
Summary

Allithiamine, a garlic compound, combats diabetes-related endothelial dysfunction by reducing advanced glycation end-products and inflammation. It shows potent antioxidant effects, offering a novel therapeutic avenue for diabetic complications.

Keywords:
advanced glycation end-productsallithiaminecytokinesgarlichyperglycaemia

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

488
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

741

Related Experiment Videos

Last Updated: Dec 18, 2025

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.4K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

488
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

741

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Diabetes mellitus poses a growing global health challenge, increasing morbidity and mortality.
  • Garlic compounds, particularly allithiamine, show potential in managing diabetes, but their specific effects require further investigation.
  • Endothelial dysfunction is a key complication of diabetes, driven by hyperglycemia and oxidative stress.

Purpose of the Study:

  • To investigate the effects of allithiamine on hyperglycaemia-induced endothelial dysfunction in human umbilical cord vein endothelial cells (HUVECs).
  • To determine if allithiamine can mitigate the production of advanced glycation end-products (AGEs) and inflammatory responses.
  • To explore the antioxidant capacity of allithiamine and its impact on oxidative stress markers.

Main Methods:

  • HUVECs were cultured and exposed to high glucose conditions to model hyperglycemia.
  • Cell viability, apoptosis, and necrosis assays were performed to determine non-cytotoxic concentrations of allithiamine.
  • Levels of AGEs, NF-κB activation, pro-inflammatory cytokines (IL-6, IL-8, TNF-α), and oxidative stress (H₂O₂) were measured.
  • Transketolase activity was assessed to explore potential mechanisms of action.

Main Results:

  • Allithiamine significantly suppressed the hyperglycaemia-induced increase in AGEs and pro-inflammatory cytokine release.
  • Allithiamine demonstrated a potent antioxidant effect, reducing oxidative stress markers.
  • No enhancement of transketolase activity was observed, suggesting a mechanism independent of this enzyme.
  • Allithiamine effectively alleviated hyperglycaemia-induced endothelial dysfunction.

Conclusions:

  • Allithiamine exerts significant antioxidant and anti-inflammatory effects, mitigating hyperglycaemia-induced endothelial dysfunction.
  • The therapeutic benefits of allithiamine in diabetes appear to be mediated through its antioxidant and anti-inflammatory properties, not via transketolase activity.
  • Allithiamine represents a promising nutraceutical for managing diabetic vascular complications.